{"summary":"Highly experienced professional with extensive expertise in basic medical and pharmaceutical sciences, cancer pathobiology, drug development, precision medicine and translational oncology, including radiopharmaceutical development of both therapeutic and imaging agents. Proven leadership and successful delivery of projects in multidisciplinary collaborative environments across academic, regulatory, industry and publishing sectors. Demonstrated self-starter and team-player with excellent communication and interpersonal skills. Passionate about translating scientific innovations into improved patient outcomes.","lastName":"Vassileva, PhD","objectUrn":"urn:li:member:135913629","geoRegion":"United Kingdom","fullName":"Vessela Vassileva, PhD","firstName":"Vessela","currentPositions":[{"companyName":"Telix Pharmaceuticals Limited","description":"\u2022\tProvide strategic direction and oversight for pharmacology and toxicology activities related to radiopharmaceutical development\n\u2022\tDesign, plan, and oversee preclinical pharmacology and toxicology studies to support regulatory submissions and product development\n\u2022\tLead, mentor, and develop team of scientists and researchers, ensuring team expertise aligns with company objectives\n\u2022\tEnsure all pharmacology and toxicology studies adhere to regulatory guidelines, including FDA, EMA, and other relevant agencies; prepare and review relevant sections of regulatory submissions\n\u2022\tCollaborate cross-functionally with other departments, including research, clinical development, regulatory affairs, and quality assurance to ensure seamless product development\n\u2022\tAnalyze and interpret pharmacological and toxicological data to guide decision-making processes and provide insights into safety and efficacy of radiopharmaceutical products\n\u2022\tConduct thorough risk assessments to identify potential safety concerns and develop strategies to mitigate risks associated with radiopharmaceutical products\n\u2022\tStay abreast of latest developments in pharmacology, toxicology, and radiopharmaceutical research, and implement best practices and innovative approaches to enhance company's product development efforts\n\u2022\tManage departmental budget effectively, ensuring optimal allocation of resources and cost-effective execution of projects\n\u2022\tEffectively communicate pharmacology and toxicology findings, recommendations, and updates to senior management, regulatory agencies, and external stakeholders","title":"Senior Manager, Pharmacology & Toxicology","companyUrnResolutionResult":{"employeeCountRange":"201-500","headquarters":{"geographicArea":"Victoria","country":"Australia","city":"North Melbourne","postalCode":"3051","line1":"55 Flemington Rd"},"website":"http:\/\/www.telixpharma.com","flagshipCompanyUrl":"https:\/\/www.linkedin.com\/company\/telixpharma\/","industry":"Biotechnology Research"},"companyUrn":"urn:li:fs_salesCompany:18067478","tenureAtCompany":{"numMonths":2},"startedOn":{"month":4,"year":2024}}],"entityUrn":"urn:li:fs_salesProfile:(ACwAAAgZ4J0BklZY1wVe4pna4XfgrqDXe2Ww-fA,NAME_SEARCH,M3YM)","profilePictureDisplayImage":{"artifacts":[{"width":100,"fileIdentifyingUrlPathSegment":"100_100\/0\/1516822339263?e=1723075200&v=beta&t=zL8qt0xMOrDWxqanVr1gtJMnm1Q47YdPLtHJg3bk1XQ","height":100},{"width":200,"fileIdentifyingUrlPathSegment":"200_200\/0\/1516822339007?e=1723075200&v=beta&t=yCagsuES--bKtlATyhU6Z3H743_uYLZC-bSfnR1N9_Q","height":200},{"width":400,"fileIdentifyingUrlPathSegment":"400_400\/0\/1516822339183?e=1723075200&v=beta&t=6yzFC1uuw-sHynDDc_IuOgUNrT2iGHiqWSe4C1QAIEc","height":400},{"width":450,"fileIdentifyingUrlPathSegment":"800_800\/0\/1516822338983?e=1723075200&v=beta&t=bn3P1qs8CVswcA-_qQaBCaPc3I7f4672Cy0retPZj88","height":450}],"rootUrl":"https:\/\/media.licdn.com\/dms\/image\/C5603AQH5EZzbLPZdUA\/profile-displayphoto-shrink_"},"projects":[],"contactInfo":{"websites":[{"$anti_abuse_annotations":[{"attributeId":97,"entityId":19,"sourceUrn":"urn:li:member:135913629"},{"attributeId":48,"entityId":19,"sourceUrn":"urn:li:member:135913629"}],"category":"COMPANY","dataSource":"LINKEDIN","url":"https:\/\/www.imperial.ac.uk\/people\/v.vassileva"}]},"industry":"Pharmaceutical Manufacturing","educations":[{"endedOn":{"year":2008},"degree":"Doctor of Philosophy - PhD","eduId":79069509,"schoolUrn":"urn:li:fs_salesSchool:3660","school":"urn:li:fs_salesSchool:3660","fieldsOfStudy":["Pharmaceutical Sciences"],"schoolName":"University of Toronto","startedOn":{"year":2003}},{"endedOn":{"year":2002},"degree":"Master of Science - MSc","eduId":616429575,"schoolUrn":"urn:li:fs_salesSchool:3660","school":"urn:li:fs_salesSchool:3660","fieldsOfStudy":["Clinical Cancer Genetics and Molecular Pathobiology"],"schoolName":"University of Toronto","startedOn":{"year":2000}},{"endedOn":{"year":1999},"degree":"Honours Bachelor of Science","eduId":616430435,"schoolUrn":"urn:li:fs_salesSchool:3660","school":"urn:li:fs_salesSchool:3660","fieldsOfStudy":["Human Biology"],"schoolName":"University of Toronto","startedOn":{"year":1995}},{"schoolName":"Runnymede Collegiate Institute","eduId":238830866}],"skills":[{"numOfEndorsement":0,"name":"Pre-clinical Studies"},{"numOfEndorsement":0,"name":"Toxicology"},{"numOfEndorsement":0,"name":"Regulatory Submissions"},{"numOfEndorsement":0,"name":"Safety and Efficacy and Toxicity Assessment"},{"numOfEndorsement":0,"name":"Biotechnology"},{"numOfEndorsement":47,"name":"Cancer"},{"numOfEndorsement":39,"name":"Oncology"},{"numOfEndorsement":16,"name":"Drug Development"},{"numOfEndorsement":41,"name":"Molecular Biology"},{"numOfEndorsement":28,"name":"Scientific Writing"},{"numOfEndorsement":29,"name":"Biochemistry"},{"numOfEndorsement":23,"name":"Pharmacology"},{"numOfEndorsement":19,"name":"Animal Models"},{"numOfEndorsement":2,"name":"Drug Safety"},{"numOfEndorsement":1,"name":"Animal Welfare"},{"numOfEndorsement":1,"name":"Foreign Languages"},{"numOfEndorsement":1,"name":"Project Management"},{"numOfEndorsement":1,"name":"Teaching"},{"numOfEndorsement":1,"name":"Team Leadership"},{"numOfEndorsement":1,"name":"Staff Management"},{"numOfEndorsement":22,"name":"Cancer Research"},{"numOfEndorsement":5,"name":"Pharmacokinetics"},{"numOfEndorsement":5,"name":"Drug Delivery"},{"numOfEndorsement":4,"name":"Translational Research"},{"numOfEndorsement":2,"name":"Molecular Genetics"},{"numOfEndorsement":2,"name":"Molecular & Cellular Biology"},{"numOfEndorsement":2,"name":"Cancer Cell Biology"},{"numOfEndorsement":2,"name":"Drug Metabolism"},{"numOfEndorsement":2,"name":"Animal Work"},{"numOfEndorsement":1,"name":"Molecular Pharmacology"},{"numOfEndorsement":1,"name":"Cancer Genomics"},{"numOfEndorsement":1,"name":"Molecular Oncology"},{"numOfEndorsement":1,"name":"colorectal cancer"},{"numOfEndorsement":0,"name":"Drug Resistance"},{"numOfEndorsement":0,"name":"Molecular Pathology"},{"numOfEndorsement":0,"name":"Gynecologic Oncology"},{"numOfEndorsement":0,"name":"Targeted Drug Delivery"},{"numOfEndorsement":0,"name":"Peer Reviews"},{"numOfEndorsement":0,"name":"Peer Mentoring"},{"numOfEndorsement":1,"name":"pre-clinical cancer models"},{"numOfEndorsement":0,"name":"Imaging - optical; SPECT"},{"numOfEndorsement":0,"name":"teaching and student supervision"},{"numOfEndorsement":0,"name":"Ovarian Cancer"},{"numOfEndorsement":0,"name":"endometrial cancer"},{"numOfEndorsement":0,"name":"Collaboration"},{"numOfEndorsement":0,"name":"Translational Science"}],"numOfConnections":1937,"patents":[],"headline":"Expert in Pharmaceutical Sciences, Cancer Biology, Drug Development, Precision Medicine and Translational Oncology","courses":[{"name":"Leadership in Action Programme"}],"certifications":[{"companyUrn":"urn:li:fs_salesCompany:11403149","url":"http:\/\/www.international.heacademy.ac.uk\/","authority":"Advance HE","name":"Higher Education Academy Fellow","company":"urn:li:fs_salesCompany:11403149","startedOn":{"month":5,"year":2015}},{"companyUrn":"urn:li:fs_salesCompany:2732681","url":"www.wilbe.com\/bsf","authority":"Wilbe | Home for entrepreneurial scientists","name":"BSF Fellow","company":"urn:li:fs_salesCompany:2732681","licenseNumber":"BSF Fellow","startedOn":{"month":4,"year":2021}}],"memberBadges":{"premium":false,"openLink":false,"jobSeeker":false},"flagshipProfileUrl":"https:\/\/www.linkedin.com\/in\/vessela-vassileva-phd-87962539","organizations":[{"name":"European Society for Medical Oncology","position":"Associate Member","startedOn":{"month":6,"year":2014}},{"name":"British Association for Cancer Research","position":"Member","startedOn":{"month":1,"year":2012}},{"name":"American Association for Pharmaceutical Scientists","position":"Member of Pharmaco-Imaging Focus Group","startedOn":{"year":2014}},{"name":"Organizing Committee for Pre-clinical Nuclear Imaging Symposium","position":"Member","startedOn":{"year":2014}},{"name":"Equality Challenge Unit Athena SWAN Charter Committee","position":"Member","startedOn":{"year":2014}}],"location":"United Kingdom","publications":[{"name":"Inflammation - the Dynamic Force of Health and Disease","publishedOn":{"month":10,"year":2014},"publisher":"Nature Publishing Group","url":"http:\/\/onlinelibrary.wiley.com\/doi\/10.1038\/clpt.2014.150\/pdf","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAgZ4J0BklZY1wVe4pna4XfgrqDXe2Ww-fA,NAME_SEARCH,M3YM)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAADDT7EByCmcD5-0AJFqSfvCvMJGFXpY7HE,NAME_SEARCH,5dlK)"}]},{"publishedOn":{"month":6,"day":1,"year":2015},"description":"Herein we report the use of next generation maleimides (NGMs) for the construction of a potent antibody-drug conjugate (ADC). The ADC, armed with monomethyl auristatin E (MMAE), shows excellent stability in blood plasma, as well as excellent potency and cancer cell selectivity in vitro.","url":"http:\/\/pubs.rsc.org\/en\/content\/articlelanding\/2015\/cc\/c5cc03557k#!divAbstract","name":"Functional native disulfide bridging enables delivery of a potent, stable and targeted antibody-drug conjugate (ADC)","publisher":"Chemical Communications","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAgZ4J0BklZY1wVe4pna4XfgrqDXe2Ww-fA,NAME_SEARCH,M3YM)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAJks7oB0PSDGja_SL6oxoSrjIfaamz2da0,NAME_SEARCH,UcZH)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAA_rB4MBheLVXK25KY1LlRT1tm1N_fQaTDI,NAME_SEARCH,RNVX)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAWQLNwB5B4N6UDd1Jp51VRqcA4j3Syml0o,NAME_SEARCH,ST2b)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAF4Q7kBUUuFz6snA1SK4TKCKt_SwPyUm5c,NAME_SEARCH,G35-)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAACPb4ABfYmS51a00biJpu2dRURXIDUH-HA, , )"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAABAlo30Bsa_iHRo2UV4FhifJFsCzzBVTa6o,NAME_SEARCH,UWRa)"}]},{"name":"Efficacy assessment of sustained intraperitoneal paclitaxel therapy in a murine model of ovarian cancer using bioluminescent imaging","publishedOn":{"year":2008},"publisher":"British Journal of Cancer","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Efficacy+assessment+of+sustained+intraperitoneal+paclitaxel+therapy+in+a+murine+model+of+ovarian+cancer+using+bioluminescent+imaging","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAgZ4J0BklZY1wVe4pna4XfgrqDXe2Ww-fA,NAME_SEARCH,M3YM)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAARrRLsByvlGFGSYuRZQ8k3EYErXyCTUst8,NAME_SEARCH,90-i)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAcIM2wB8PLLVyqK5uir2EjeQ4jE3DEbQhw,NAME_SEARCH,16D9)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAcPWK4Bsnp7R_9Z0xBl6JpURM_Y6lP-iaY,NAME_SEARCH,pNaU)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAA7FDLwBBfbaAQ_2ylJstOXejebBrLzAKtg,NAME_SEARCH,0tih)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAADDT7EByCmcD5-0AJFqSfvCvMJGFXpY7HE,NAME_SEARCH,5dlK)"}]},{"name":"Significant therapeutic efficacy with combined radioimmunotherapy and cetuximab in pre-clinical models of colorectal cancer","publishedOn":{"month":6,"year":2015},"publisher":"Journal of Nuclear Medicine","url":"http:\/\/jnm.snmjournals.org\/content\/early\/2015\/05\/29\/jnumed.115.157362.long","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAgZ4J0BklZY1wVe4pna4XfgrqDXe2Ww-fA,NAME_SEARCH,M3YM)"}]},{"name":"Efficacy assessment of sustained intraperitoneal paclitaxel therapy in a murine model of ovarian cancer using bioluminescent imaging","publishedOn":{"year":2008},"publisher":"British Journal of Cancer","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Efficacy+assessment+of+sustained+intraperitoneal+paclitaxel+therapy+in+a+murine+model+of+ovarian+cancer+using+bioluminescent+imaging","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAgZ4J0BklZY1wVe4pna4XfgrqDXe2Ww-fA,NAME_SEARCH,M3YM)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAARrRLsByvlGFGSYuRZQ8k3EYErXyCTUst8,NAME_SEARCH,90-i)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAcIM2wB8PLLVyqK5uir2EjeQ4jE3DEbQhw,NAME_SEARCH,16D9)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAcPWK4Bsnp7R_9Z0xBl6JpURM_Y6lP-iaY,NAME_SEARCH,pNaU)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAA7FDLwBBfbaAQ_2ylJstOXejebBrLzAKtg,NAME_SEARCH,0tih)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAADDT7EByCmcD5-0AJFqSfvCvMJGFXpY7HE,NAME_SEARCH,5dlK)"}]},{"name":"Interleukin-6 as a therapeutic target in human ovarian cancer","publishedOn":{"year":2011},"publisher":"Clinical Cancer Research","url":"http:\/\/10.1158\/1078-0432.CCR-11-0945","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAgZ4J0BklZY1wVe4pna4XfgrqDXe2Ww-fA,NAME_SEARCH,M3YM)"}]},{"name":"Effects of sustained and intermittent paclitaxel therapy on tumor repopulation in ovarian cancer","publishedOn":{"year":2008},"publisher":"Molecular Cancer Therapeutics","url":"http:\/\/10.1158\/1535-7163.MCT-07-2117","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAgZ4J0BklZY1wVe4pna4XfgrqDXe2Ww-fA,NAME_SEARCH,M3YM)"}]},{"name":"Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model","publishedOn":{"year":2007},"publisher":"Cancer Chemotherapy and Pharmacology","url":"http:\/\/link.springer.com\/article\/10.1007%2Fs00280-007-0449-0","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAgZ4J0BklZY1wVe4pna4XfgrqDXe2Ww-fA,NAME_SEARCH,M3YM)"}]},{"name":"In vitro and in vivo characterization of a novel biocompatible polymer-lipid implant system for the sustained delivery of paclitaxel","publishedOn":{"year":2005},"publisher":"Journal of Controlled Release","url":"http:\/\/www.sciencedirect.com\/science\/article\/pii\/S016836590500057X","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAgZ4J0BklZY1wVe4pna4XfgrqDXe2Ww-fA,NAME_SEARCH,M3YM)"}]},{"name":"Impact of endotoxin-induced changes in P-glycoprotein expression on disposition of doxorubicin in mice","publishedOn":{"year":2005},"publisher":"Drug Metabolism and Disposition","url":"http:\/\/dmd.aspetjournals.org\/content\/33\/6\/820.long","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAgZ4J0BklZY1wVe4pna4XfgrqDXe2Ww-fA,NAME_SEARCH,M3YM)"}]},{"name":"Apoptotic and growth regulatory genes as mutational targets in mismatch repair deficient endometrioid adenocarcinomas of young patients","publishedOn":{"year":2004},"publisher":"Oncology Reports","url":"https:\/\/www.spandidos-publications.com\/or\/11\/4\/931","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAgZ4J0BklZY1wVe4pna4XfgrqDXe2Ww-fA,NAME_SEARCH,M3YM)"}]},{"name":"Genes involved in DNA repair are mutational targets in endometrial cancers with microsatellite instability","publishedOn":{"year":2002},"publisher":"Cancer Research","url":"http:\/\/cancerres.aacrjournals.org\/content\/62\/14\/4095.long","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAgZ4J0BklZY1wVe4pna4XfgrqDXe2Ww-fA,NAME_SEARCH,M3YM)"}]},{"name":"Inflammation: extinguishing the fires within","publishedOn":{"year":2010},"publisher":"Clinical Pharmacology and Therapeutics","url":"http:\/\/onlinelibrary.wiley.com\/doi\/10.1038\/clpt.2010.10\/abstract;jsessionid=B56D2F0663F666730394F503CA08FD17.f04t04","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAgZ4J0BklZY1wVe4pna4XfgrqDXe2Ww-fA,NAME_SEARCH,M3YM)"}]}],"positions":null,"posts":[{"createdAt":1710616980000,"insightId":"1f29f379-4f20-494b-a74d-19b976bf5b7b","activityUnion":{"postActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":5}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:ugcPost:7174847756740546560","threadUrn":"urn:li:ugcPost:7174847756740546560","reactionsCount":5,"commentsCount":0,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7174847756740546560","message":{"attributes":[{"start":26,"length":20,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:universityoftoronto"}}},{"start":47,"length":21,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:3660"}}},{"start":69,"length":5,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:uoft"}}},{"start":75,"length":8,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:hbduoft"}}}],"text":"Happy birthday U of T! \ud83e\udd73 #universityoftoronto University of Toronto #UofT #HBDUofT"},"rootActivity":{"contentSummaryUnion":{"mediaContentSummary":{"title":{"text":"Happy Birthday, U of T!"},"mediaType":"VIDEO","thumnailUrl":"https:\/\/dms.licdn.com\/playlist\/vid\/D5610AQGbBKfb6VRtXg\/videocover-firstframe-low\/0\/1710509529742?e=1717977600&v=beta&t=BpHF-Em2nrTHLyJiTYAds6U39fIfze53LvJpdwvxdsY"}},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7174397010911924224","message":{"attributes":[{"start":115,"length":5,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:uoft"}}},{"start":129,"length":8,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:hbduoft"}}}],"text":"197 years young and still burning bright! Help us blow out our candles, drop a \ud83e\udd73 in the comments. Happy birthday, #UofT! \ud83c\udf82\ud83c\udf88\ud83d\udc99 #HBDUofT "},"entityUrn":"urn:li:ugcPost:7174397010911924224"},"entityUrn":"urn:li:ugcPost:7174847756740546560"}}},{"createdAt":1710305760000,"insightId":"21984b80-4af7-457d-8771-6614d4e9e7a0","activityUnion":{"postActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":2}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:activity:7173542322654076928","threadUrn":"urn:li:activity:7173542322654076928","reactionsCount":2,"commentsCount":0,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7173542322125701120","message":{"attributes":[],"text":"Exciting research opportunity!"},"rootActivity":{"contentSummaryUnion":{"ingestedContentSummary":{"image":{"attributes":[{"originalImageUrl":"https:\/\/media.licdn.com\/dms\/image\/sync\/D4E27AQFKkAJC4Atchw\/articleshare-shrink_800\/0\/1711278687731?e=1717977600&v=beta&t=Ht8yhMNi2oBwMH7a_BBd_OsxETaorrlCnwCDejcN0l4","sourceType":"URL","imageUrl":"https:\/\/media.licdn.com\/dms\/image\/sync\/D4E27AQFKkAJC4Atchw\/articleshare-shrink_800\/0\/1711278687731?e=1717977600&v=beta&t=Ht8yhMNi2oBwMH7a_BBd_OsxETaorrlCnwCDejcN0l4"}]},"description":"Explore an exciting academic career as a Post-Doctoral Research Associate. Don't miss out on other academic jobs. Click to apply and explore more opportunities.","fullText":"Back to search results Location: Hammersmith Hospital Campus You will join Profs Ali and Buluwela\u2019s laboratory in the Division of Cancer. The team focuses on discovering mechanisms of drug resistance and metastasis in breast cancer and translating these into new therapies. Recent successes include the identification of CDK7 as a new therapeutic target for breast cancer, discovery of an oral CDK7 inhibitor and its progression to clinical trials. We employ functional genomic screens, proteomics, RNA-seq and ChIP-seq for identifying mechanisms of resistance and targetable vulnerabilities. These data are validated in pre-clinical findings from 2D\/3D models using gene manipulation and selective drugs. The post will be focused on investigating mechanisms by which mutations in the estrogen receptor (ER) drive therapy resistance and metastasis in breast cancer patients. The postholder will lead the work to exploit our unique resource of ER-mutant breast cancer models. This will include undertaking transcriptomic\/epigenomic profiling to discover new therapeutic approaches for treating patients with treatment-resistant, metastatic breast cancer. In addition, the candidate will provide support\/training to research staff, MRes, MD and PhD students within or associated with the group. ( *Candidates who have not yet been officially awarded their PhD will be appointed as a Research Assistant within the salary range \u00a340,694 to \u00a343,888 per annum) This position is full time, fixed term for 3 years. Should you require any further details on the role please contact: Prof Simak Ali ( simak.ali@imperial.ac.uk ) We value your feedback on the quality of our adverts. If you have a comment to make about the overall quality of this advert, or its categorisation then please send us your feedback","resolvedUrl":"https:\/\/www.jobs.ac.uk\/job\/DGK140\/post-doctoral-research-associate","title":"Post-Doctoral Research Associate at Imperial College London","sourceDomain":"jobs.ac.uk"}},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7172551250847219712","message":{"attributes":[{"start":384,"length":24,"value":{"com.linkedin.common.HyperlinkAttributedEntity":{"url":"https:\/\/lnkd.in\/em_wdyvD"}}}],"text":"Mutations in the estrogen receptor gene are important drivers of resistance to therapy in metastatic breast cancer. Applications wanted from post-docs to use transcriptomics and genome engineering for revealing mechanisms and identify new therapies. Our group has excellent expertise in these areas and has a track record in translating laboratory findings to cancer clinical trials.\nhttps:\/\/lnkd.in\/em_wdyvD "},"entityUrn":"urn:li:share:7172551250847219712"},"entityUrn":"urn:li:share:7173542322125701120"}}},{"createdAt":1715251140000,"insightId":"31a06ad1-4805-4f3c-925a-a67ba2169d7b","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(activity:7193300452405366784,7194284769411575808)","threadUrn":"urn:li:activity:7193300452405366784","reactionsCount":1,"commentsCount":1,"canComment":true},"commentary":{"attributes":[],"text":"Congrats, Fabian! Very exciting! "},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:activity:7193300452405366784"}}},{"createdAt":1713466440000,"insightId":"13d310e2-7d0d-4833-bd73-bd4fb2bf801a","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7186687384674025472,7186799392614486017)","threadUrn":"urn:li:ugcPost:7186687384674025472","reactionsCount":0,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"Looks so lightweight in the photo\u2026.how misleading!"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7186687384674025472"}}},{"createdAt":1710946800000,"insightId":"278e084c-d1e2-4d81-b692-e6b901984b42","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(activity:7175835094861938690,7176231160895737856)","threadUrn":"urn:li:activity:7175835094861938690","reactionsCount":1,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"Exciting developments await! Anticipating the evolution of next-gen radiopharmaceuticals!"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:activity:7175835094861938690"}}},{"createdAt":1710946200000,"insightId":"53964037-17f1-4833-85a2-60d03ee7aa35","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(activity:7175984210355048449,7176228579414880256)","threadUrn":"urn:li:activity:7175984210355048449","reactionsCount":1,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"Congratulations!"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:activity:7175984210355048449"}}},{"createdAt":1709657400000,"insightId":"7b9f2fe1-395d-4d2d-ade0-5a041728d875","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7170453223747641346,7170823075658223617)","threadUrn":"urn:li:ugcPost:7170453223747641346","reactionsCount":1,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"How exciting! Congrats!"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7170453223747641346"}}}]}